Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04124003 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04124003 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 28 participants.
The verdict
NCT04124003, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants
Interventions
- DRUG rosuvastatin
- DRUG BMS-963272
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-10-08 |
| Est. Completion | 2020-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04124003
The ClinicalTrials.gov registry entry for NCT04124003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rosuvastatin is the first listed.
NCT04124003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04124003 about?
NCT04124003 is a clinical study titled "A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin". Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants
What is the current status of trial NCT04124003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-10-08. Estimated completion is 2020-01-03.
What interventions are being tested in trial NCT04124003?
The interventions under investigation include: rosuvastatin (DRUG), BMS-963272 (DRUG).
Who is sponsoring clinical trial NCT04124003?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.